Beijing Luzhu Biotech publishes 2025 annual report

  • Beijing Luzhu Biotechnology released annual report for year ended Dec. 31, 2025, highlighting continued push toward commercialization of core shingles vaccine candidate LZ901.
  • LZ901 China filing advanced with BLA submitted in January 2025, accepted in February 2025.
  • NMPA completed clinical trial on-site inspection plus production site inspection in Q3 2025; company targets PRC commercialization in H2 2026.
  • US Phase I trial for LZ901 completed in September 2025 with 66 subjects enrolled, supporting next-stage overseas development.
  • Pipeline broadened with recombinant RSV vaccine moving into pre-IND stage in 2025; recombinant HSV-2 vaccine targeted for pre-IND as early as H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Luzhu Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260423-12119839), on April 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.